Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Benitec Biopharma (BNTC) over the last 5 years, with Jun 2025 value amounting to $6.1 million.

  • Benitec Biopharma's Share-based Compensation rose 1245.59% to $6.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $17.4 million, marking a year-over-year increase of 1999.52%. This contributed to the annual value of $17.4 million for FY2025, which is 1999.52% up from last year.
  • As of Q2 2025, Benitec Biopharma's Share-based Compensation stood at $6.1 million, which was down 21.11% from $7.7 million recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's Share-based Compensation ranged from a high of $7.7 million in Q1 2025 and a low of -$48,000 during Q4 2022.
  • In the last 3 years, Benitec Biopharma's Share-based Compensation had a median value of $313,500 in 2024 and averaged $1.8 million.
  • In the last 5 years, Benitec Biopharma's Share-based Compensation slumped by 120.08% in 2022 and then spiked by 3,933.33% in 2025.
  • Benitec Biopharma's Share-based Compensation (Quarterly) stood at $239,000 in 2021, then tumbled by 120.08% to -$48,000 in 2022, then soared by 293.75% to $93,000 in 2023, then soared by 3,274.19% to $3.1 million in 2024, then surged by 1,245.59% to $6.1 million in 2025.
  • Its Share-based Compensation stands at $6.1 million for Q2 2025, versus $7.7 million for Q1 2025 and $3.1 million for Q4 2024.